Shanghai Pharmaceuticals Holding Co., Ltd. (02607) published its unaudited third-quarter results for 2025. From January to September, the company recorded operating revenue of RMB215.072 billion, up by 2.60% year on year, of which pharmaceutical manufacturing contributed RMB18.164 billion (-0.66% year on year) and pharmaceutical services RMB196.908 billion (+2.91% year on year). Net profit attributable to the listed company’s shareholders reached RMB5.147 billion, marking a 26.96% increase year on year, driven partly by one-off gains arising from accounting changes. Excluding those items, net profit was RMB3.979 billion, representing a slight decrease of 1.85% compared with the same period last year.

In the third quarter, Shanghai Pharmaceuticals continued to strengthen its R&D initiatives, investing RMB1.729 billion, which accounted for 9.52% of its pharmaceutical manufacturing revenue. The company highlighted successful progress in multiple innovative drug pipelines, including biologics targeting IL-17, TCM products under evidence-based medicine research, and new CAR-T therapeutic projects. Meanwhile, its strategic efforts in traditional Chinese medicine resulted in product-line expansions for leading brands, alongside further exploration into overseas markets.

By the end of the reporting period, Shanghai Pharmaceuticals managed 51 products designated for the treatment of rare diseases, covering over 60 conditions. In its pharmaceutical services segment, the company reported solid growth, with accelerated performance in innovative drugs, import agency, devices business, and new retail initiatives. During January to September, the net cash inflow from operating activities remained robust at RMB2.350 billion.

According to the announcement, the management will continue to advance the company’s strategic focus on Chinese and Western medicines, maintaining an emphasis on R&D, supply chain collaborations, and international market development.